BB Biotech Presents 23% Nine-Month NAV Gain in Swiss Francs

By Public Technologies
  • BB Biotech’s net asset value rose 23% in CHF over the first nine months of 2026, trailing the NBI’s 31.8% gain.
  • Its share price gained 21.5% in CHF over the same period.
  • CHF 280 million from the Crinetics Pharmaceuticals and Nuvalent acquisitions was reinvested within the third quarter.
  • Revolution Medicines was reduced from more than 11% of NAV to around 5% as its shares more than doubled.
  • The annual dividend yield target is 3–5% from fiscal 2026, with the first payment expected in spring 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BB Biotech AG published the original content used to generate this news brief on October 22, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.